Adenosine and Brain Function

International Review of Neurobiology

Volumn 63, Issue , 2005, Pages 191-270

  Fredholm, Bertil B ^a   Chen, Jiang Fan ^b   Cunha, Rodrigo A ^c   Svenningsson, Per ^a   Vaugeois, Jean Marie ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITÉ DE ROUEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR;

ANIMAL; BRAIN; BRAIN LEVEL; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ADENOSINE; ANIMALS; BRAIN; BRAIN CHEMISTRY; HUMANS; RECEPTORS, PURINERGIC P1;

EID: 17844403763     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(05)63007-3     Document Type: Article

References (532)

1. 3 receptors in rat brain. Mol. Pharmacol. 48 (1995) 1038-1045
2. 3 receptors and viability in astrocytes. Drug Dev. Res. 45 (1998) 379-386
3. Abo-Salem O.M., Hayallah A.M., Bilkei-Gorzo A., Filipek B., Zimmer A., and Müller C.E. Antinociceptive effects of novel A2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. 308 (2004) 358-366
4. Acquas E., Tanda G., and Di Chiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology 27 (2002) 182-193
5. 2A knockout mice. Stroke 34 (2003) 739-744
6. 1 receptor agonism in the immature rat brain and heart. Eur. J. Pharmacol. 426 (2001) 185-192
7. Ahlijanian M.K., and Takemori A.E. Effects of (-)-N6-(R-phenylisopropyl)-adenosine (PIA) and caffeine on nociception and morphine-induced analgesia, tolerance and dependence. Eur. J. Pharmacol. 112 (1985) 171-179
8. Alam M.N., Szymusiak R., Gong H., King J., and McGinty D. Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: Neuronal recording with microdialysis. J. Physiol. (Lond.) 521 Pt 3 (1999) 679-690
9. Alanko L., Heiskanen S., Stenberg D., and Porkka-Heiskanen T. Adenosine kinase and 5′-nucleotidase activity after prolonged wakefulness in the cortex and the basal forebrain of rat. Neurochem. Int. 42 (2003) 449-454
10. Alfinito P.D., Wang S.P., Manzino L., Rijhsinghani S., Zeevalk G.D., and Sonsalla P.K. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 23 (2003) 10982-10987
11. Alsene K., Deckert J., Sand P., and de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28 (2003) 1694-1702
12. Alzheimer C., Sutor B., and ten Bruggencate G. Disinhibition of hippocampal CA3 neurons induced by suppression of an adenosine A1 receptor-mediated inhibitory tonus: Pre- and postsynaptic components. Neuroscience 57 (1993) 565-575
13. 2+ channels in rat hippocampal nerve terminals by the adenosine A1 receptor. Eur. J. Pharmacol. 340 (1997) 301-310
14. Andersen M.B., Fuxe K., Werge T., and Gerlach J. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav. Pharmacol. 13 (2002) 639-644
15. Angelucci M.E., Cesário C., Hiroi R.H., Rosalen P.L., and Da Cunha C. Effects of caffeine on learning and memory in rats tested in the Morris water maze. Braz. J. Med. Biol. Res. 35 (2002) 1201-1208
16. Angers S., Salahpour A., and Bouvier M. Dimerization: An emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 409-435
17. Angulo E., Casadó V., Mallol J., Canela E.I., Viñals F., Ferrer I., Lluis C., and Franco R. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 13 (2003) 440-451
18. Aoyama S., Kase H., and Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J. Neurosci. 20 (2000) 5848-5852
19. Arcuino G., Lin J.H., Takano T., Liu C., Jiang L., Gao Q., Kang J., and Nedergaard M. Intercellular calcium signaling mediated by point-source burst release of ATP. Proc. Natl. Acad. Sci. USA 99 (2002) 9840-9845
20. Ascherio A., Chen H., Schwarzschild M.A., Zhang S.M., Colditz G.A., and Speizer F.E. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60 (2003) 790-795
21. Ascherio A., Zhang S.M., Hernam M.A., Kawachi I., Colditz G.A., Speizer F.E., and Willett W.C. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50 (2001) 56-63
22. Atkinson M.R., Townsend-Nicholson A., Nicholl J.K., Sutherland G.R., and Schofield P.R. Cloning, characterization and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene. Neurosci. Res. 29 (1997) 73-79
23. Auchampach J.A., Jin X., Wan T.C., Caughey G.H., and Linden J. Canine mast cell adenosine receptors: Cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mol. Pharmacol. 52 (1997) 846-860
24. Augood S.J., and Emson P.C. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: A co-expression study. Brain Res. Mol. 22 (1994) 204-210
25. Ault B., Olney M.A., Joyner J.L., Boyer C.E., Notrica M.A., Soroko F.E., and Wang C.M. Pro-convulsant actions of theophylline and caffeine in the hippocampus: Implications for the management of temporal lobe epilepsy. Brain Res. 426 (1987) 93-102
26. Baker S.P., Scammells P.J., and Belardinelli L. Differential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cells. Br. J. Pharmacol. 130 (2000) 1156-1164
27. Ballarín M., Fredholm B.B., Ambrosio S., and Mahy N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: Inhibition of uptake and metabolism. Acta Physiol. Scand. 142 (1991) 97-103
28. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., Morris M.J., Mouradian M.M., and Chase T.N. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
29. Baraldi P.G., Cacciari B., Romagnoli R., Merighi S., Varani K., Borea P.A., and Spalluto G. A(3) adenosine receptor ligands: History and perspectives. Med. Res. Rev. 20 (2000) 103-128
30. Baraldi P.G., Romagnoli R., Pavani M.G., Nuñez Mdel C., Tabrizi M.A., Shryock J.C., Leung E., Moorman A.R., Uluoglu C., Iannotta V., Merighi S., and Borea P.A. Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptor. J. Med. Chem. 46 (2003) 794-809
31. Barnes C.A. Normal aging: Regionally specific changes in hippocampal synaptic transmission. Trends Neurosci. 17 (1994) 13-18
32. Barrie A.P., and Nicholls D.G. Adenosine A1 receptor inhibition of glutamate exocytosis and protein kinase C-mediated decoupling. J. Neurochem. 60 (1993) 1081-1086
33. Basheer R., Arrigoni E., Thatte H.S., Greene R.W., Ambudkar I.S., and McCarley R.W. Adenosine induces inositol 1,4,5-trisphosphate receptor-mediated mobilization of intracellular calcium stores in basal forebrain cholinergic neurons. J. Neurosci. 22 (2002) 7680-7686
34. 2A receptor mRNA in the rat following sleep deprivation. Neuroreport 12 (2001) 1577-1580
35. Basheer R., Porkka-Heiskanen T., Stenberg D., and McCarley R.W. Adenosine and behavioral state control: Adenosine increases c-Fos protein and AP1 binding in basal forebrain of rats. Brain Res. Mol. Brain Res. 73 (1999) 1-10
36. Basheer R., Porkka-Heiskanen T., Strecker R.E., Thakkar M.M., and McCarley R.W. Adenosine as a biological signal mediating sleepiness following prolonged wakefulness. Biol. Signals Recept. 9 (2000) 319-327
37. Bedingfield J.B., King D.A., and Holloway F.A. Cocaine and caffeine: Conditioned place preference, locomotor activity, and additivity. Pharmacol. Biochem. Behav. 61 (1998) 291-296
38. Behan W.M., and Stone T.W. Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br. J. Pharmacol. 135 (2002) 1435-1442
39. Bengzon J., Kokaia Z., Elmér E., Nanobashvili A., Kokaia M., and Lindvall O. Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures. Proc. Natl. Acad. Sci. USA 94 (1997) 10432-10437
40. 1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res. 692 (1995) 79-85
41. Benveniste H., Hansen A.J., and Ottosen N.S. Determination of brain interstitial concentrations by microdialysis. J. Neurochem. 52 (1989) 1741-1750
42. Berman R.F., Fredholm B.B., Ådén U., and O'Connor W.T. Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats. Brain Res. 872 (2000) 44-53
43. Berrendero F., Castañé A., Ledent C., Parmentier M., Maldonado R., and Valverde O. Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. Eur. J. Neurosci. 17 (2003) 315-324
44. Bibb J.A., Snyder G.L., Nishi A., Yan Z., Meijer L., Fienberg A.A., Tsai L.H., Kwon Y.T., Girault J.A., Czernik A.J., Huganir R.L., Hemmings Jr. H.C., Nairn A.C., and Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402 (1999) 669-671
45. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Chen J.F., Schwarzschild M.A., and Chase T.N. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184 (2003) 285-294
46. Biber K., Klotz K.N., Berger M., Gebicke-Härter P.J., and van Calker D. Adenosine A1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J. Neurosci. 17 (1997) 4956-4964
47. Blum D., Galas M.C., Gall D., Cuvelier L., and Schiffmann S.N. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol. Dis. 10 (2002) 410-426
48. Blum D., Gall D., Galas M.C., d'Alcantara P., Bantubungi K., and Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 22 (2002) 9122-9133
49. Bodas E., Aleu J., Pujol G., Martin-Satué M., Marsal J., and Solsona C. ATP crossing the cell plasma membrane generates an ionic current in xenopus oocytes. J. Biol. Chem. 275 (2000) 20268-20273
50. Bodin P., and Burnstock G. Purinergic signalling: ATP release. Neurochem. Res. 26 (2001) 959-969
51. Bona E., Ådén U., Fredholm B.B., and Hagberg H. The effect of long term caffeine treatment on hypoxic-ischemic brain damage in the neonate. Pediat. Res. 38 (1995) 312-318
52. Bonan C.D., Amaral O.B., Rockenbach I.C., Walz R., Battastini A.M., Izquierdo I., and Sarkis J.J. Altered ATP hydrolysis induced by pentylenetetrazol kindling in rat brain synaptosomes. Neurochem. Res. 25 (2000) 775-779
53. Bonan C.D., Walz R., Pereira G.S., Worm P.V., Battastini A.M., Cavalheiro E.A., Izquierdo I., and Sarkis J.J. Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy. Epilepsy Res. 39 (2000) 229-238
54. Bonci A., and Williams J.T. A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 16 (1996) 631-639
55. Boulenger J.P., Uhde T.W., Wolff E.A., and Post R.M. Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch. Gen. Psychiatry 41 (1984) 1067-1071
56. Bové J., Marin C., Bonastre M., and Tolosa E. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 46 (2002) 251-257
57. Brodie C., Blumberg P.M., and Jacobson K.A. Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett. 429 (1998) 139-142
58. Brooke R.E., Deuchars J., and Deuchars S.A. Input-specific modulation of neurotransmitter release in the lateral horn of the spinal cord via adenosine receptors. J. Neurosci. 24 (2004) 127-137
59. Brundege J.M., Diao L., Proctor W.R., and Dunwiddie T.V. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. Neuropharmacology 36 (1997) 1201-1210
60. Bruns R.F., and Fergus J.H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38 (1990) 939-949
61. Bunzow J.R., Van Tol H.H., Grandy D.K., Albert P., Salon J., Christie M., Machida C.A., Neve K.A., and Civelli O. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336 (1988) 783-787
62. Caciagli F., Ciccarelli R., Di Iorio P., Ballerini P., and Tacconelli L. Cultures of glial cells release purines under field electrical stimulation: The possible ionic mechanisms. Pharmacol. Res. Commun. 20 (1988) 935-947
63. 2 receptor-receptor heteromerization. J. Biol. Chem. 278 (2003) 46741-46749
64. Carruthers A.M., Sellers L.A., Jenkins D.W., Jarvie E.M., Feniuk W., and Humphrey P.P. Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons. Mol. Pharmacol. 59 (2001) 1533-1541
65. Cassada D.C., Tribble C.G., Long S.M., Kaza A.K., Linden J., Rieger J.M., Rosin D., Kron I.L., and Kern J.A. Adenosine A2A agonist reduces paralysis after spinal cord ischemia: Correlation with A2A receptor expression on motor neurons. Ann. Thorac. Surg. 74 (2002) 846-849 discussion 849.
66. Cavazos J.E., Das I., and Sutula T.P. Neuronal loss induced in limbic pathways by kindling: Evidence for induction of hippocampal sclerosis by repeated brief seizures. J. Neurosci. 14 (1994) 3106-3121
67. Ceballos G., Tuttle J.B., and Rubio R. Differential distribution of purine metabolizing enzymes between glia and neurons. J. Neurochem. 62 (1994) 1144-1153
68. Cerniway R.J., Yang Z., Jacobson M.A., Linden J., and Matherne G.P. Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H1751-H1758
69. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. Biol. 354 (1999) 981-989
70. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., and Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. USA 95 (1998) 6480-6485
71. Chen J.F., Beilstein M., Xu Y.H., Turner T.J., Moratalla R., Standaert D.G., Aloyo V.J., Fink J.S., and Schwarzschild M.A. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience 97 (2000) 195-204
72. Chen J.F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., Moskowitz M.A., Fink J.S., and Schwarzschild M.A. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19 (1999) 9192-9200
73. Chen J.F., Moratalla R., Impagnatiello F., Grandy D.K., Cuellar B., Rubinstein M., Beilstein M.A., Hackett E., Fink J.S., Low M.J., Ongini E., and Schwarzschild M.A. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A[2A]R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc. Natl. Acad. Sci. USA 98 (2001) 1970-1975
74. Chen J.F., Moratalla R., Yu L., Martín A.B., Xu K., Bastia E., Hackett E., Alberti I., and Schwarzschild M.A. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology 28 (2003) 1086-1095
75. Chen J.F., Xu K., Petzer J.P., Staal R., Xu Y.H., Beilstein M., Sonsalla P.K., Castagnoli K., Castagnoli N., and Schwarzschild M.A. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 (2001) RC143
76. Choi D.S., Cascini M.G., Mailliard W., Young H., Paredes P., McMahon T., Diamond I., Bonci A., and Messing R.O. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat. Neurosci. 7 (2004) 855-861
77. Chu Y.Y., Tu K.H., Lee Y.C., Kuo Z.J., Lai H.L., and Chern Y. Characterization of the rat A2a adenosine receptor gene. DNA Cell Biol. 15 (1996) 329-337
78. Ciccarelli R., Ballerini P., Sabatino G., Rathbone M.P., D'Onofrio M., Caciagli F., and Di Iorio P. Involvement of astrocytes in purine-mediated reparative processes in the brain. Int. J. Dev. Neurosci. 19 (2001) 395-414
79. Ciccarelli R., Di Iorio P., Ballerini P., Ambrosini G., Giuliani P., Tiboni G.M., and Caciagli F. Effects of exogenous ATP and related analogues on the proliferation rate of dissociated primary cultures of rat astrocytes. J. Neurosci. Res. 39 (1994) 556-566
80. Ciccarelli R., Di Iorio P., Bruno V., Battaglia G., D'Alimonte I., D'Onofrio M., Nicoletti F., and Caciagli F. Activation of A(1) adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. Glia 27 (1999) 275-281
81. Ciruela F., Escriche M., Burgueno J., Angulo E., Casado V., Soloviev M.M., Canela E.I., Mallol J., Chan W.Y., Lluis C., McIlhinney R.A., and Franco R. Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J. Biol. Chem. 276 (2001) 18345-18351
82. Ciruela F., Saura C., Canela E.I., Mallol J., Lluis C., and Franco R. Ligand-induced phosphorylation, clustering, and desensitization of A1 adenosine receptors. Mol. Pharmacol. 52 (1997) 788-797
83. Coco S., Calegari F., Pravettoni E., Pozzi D., Taverna E., Rosa P., Matteoli M., and Verderio C. Storage and release of ATP from astrocytes in culture. J. Biol. Chem. 278 (2003) 1354-1362
84. Coney A.M., and Marshall J.M. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. J. Physiol. (Lond.) 509 (1998) 507-518
85. Corodimas K.P., and Tomita H. Adenosine A1 receptor activation selectively impairs the acquisition of contextual fear conditioning in rats. Behav. Neurosci. 115 (2001) 1283-1290
86. Correia-de-Sa P., and Ribeiro J.A. Potentiation by tonic A2a-adenosine receptor activation of CGRP-facilitated :3H:-ACh release from rat motor nerve endings. Br. J. Pharmacol. 111 (1994) 582-588
87. 3H]acetylcholine release from the rat motor nerve terminals. Neuroscience 73 (1996) 85-92
88. Correia-de-Sa P., Timoteo M.A., and Ribeiro J.A. Presynaptic A1 inhibitory/A2A facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. J. Neurophysiol. 76 (1996) 3910-3919
89. Corset V., Nguyen-Ba-Charvet K.T., Forcet C., Moyse E., Chedotal A., and Mehlen P. Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor. Nature 407 (2000) 747-750
90. Costenla A.R., Lopes L.V., de Mendonça A., and Ribeiro J.A. A functional role for adenosine A3 receptors: Modulation of synaptic plasticity in the rat hippocampus. Neurosci. Lett. 302 (2001) 53-57
91. Couturier E.G., Laman D.M., van Duijn M.A., and van Duijn H. Influence of caffeine and caffeine withdrawal on headache and cerebral blood flow velocities. Cephalalgia 17 (1997) 188-190
92. 2 generation, respectively. J. Clin. Invest. 85 (1990) 1150-1157
93. Cronstein B.N., Kramer S.B., Weissmann G., and Hirschhorn R. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. J. Exp. Med. 158 (1983) 1160-1177
94. Cunha R.A. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: Different roles, different sources and different receptors. Neurochem. Int. 38 (2001) 107-125
95. Cunha R.A. Regulation of the ecto-nucleotidase pathway in rat hippocampal nerve terminals. Neurochem. Res. 26 (2001) 979-991
96. Cunha R.A., Almeida T., and Ribeiro J.A. Parallel modification of adenosine extracellular metabolism and modulatory action in the hippocampus of aged rats. J. Neurochem. 76 (2001) 372-382
97. Cunha R.A., Constantino M.C., Sebastiao A.M., and Ribeiro J.A. Modification of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport 6 (1995) 1583-1588
98. Cunha R.A., Constantino M.D., Fonseca E., and Ribeiro J.A. Age-dependent decrease in adenosine A1 receptor binding sites in the rat brain. Effect of cis unsaturated free fatty acids. Eur. J. Biochem. 268 (2001) 2939-2947
99. Cunha R.A., Correia-de-Sá P., Sebastião A.M., and Ribeiro J.A. Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. Br. J. Pharmacol. 119 (1996) 253-260
100. 2A receptors. Naunyn Schmiedebergs Arch. Pharmacol. 353 (1996) 261-271
101. 2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci. Lett. 196 (1995) 41-44
102. 3H]acetylcholine release from different areas of the rat hippocampus. J. Neurochem. 63 (1994) 207-214
103. Cunha R.A., and Ribeiro J.A. Purinergic modulation of [(3)H]GABA release from rat hippocampal nerve terminals. Neuropharmacology 39 (2000) 1156-1167
104. Cunha R.A., and Ribeiro J.A. Adenosine A2A receptor facilitation of synaptic transmission in the CA1 area of the rat hippocampus requires protein kinase C but not protein kinase A activation. Neurosci. Lett. 289 (2000) 127-130
105. Cunha R.A., Sebastião A.M., and Ribeiro J.A. Inhibition by ATP of hippocampal synaptic transmission requires localized extracellular catabolism by ecto-nucleotidases into adenosine and channeling to adenosine A1 receptors. J. Neurosci. 18 (1998) 1987-1995
106. Cunha R.A., Vizi E.S., Ribeiro J.A., and Sebastião A.M. Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices. J. Neurochem. 67 (1996) 2180-2187
107. d'Alcantara P., Ledent C., Swillens S., and Schiffmann S.N. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107 (2001) 455-464
108. Dale N. Resetting intrinsic purinergic modulation of neural activity: An associative mechanism?. J. Neurosci. 22 (2002) 10461-10469
109. Dall'lgna O.P., Porciúncula L.O., Souza D.O., Cunha R.A., and Lara D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol. 138 (2003) 1207-1209
110. Daly J.W. "Cyclic Nucleotides in the Nervous System." (1977), Plenum Press, New York
111. Daly J.W., and Fredholm B.B. Caffeine-an atypical drug of dependence. Drug Alcohol Depend. 51 (1998) 199-206
112. Dassesse D., Massie A., Ferrari R., Ledent C., Parmentier M., Arckens L., Zoli M., and Schiffmann S.N. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J. Neurochem. 78 (2001) 183-198
113. De Lander G.E., and Hopkins C.J. Spinal adenosine modulates descending antinociceptive pathways stimulated by morphine. J. Pharmacol. Exp. Ther. 239 (1986) 88-93
114. de Mendonça A., and Ribeiro J.A. Adenosine and neuronal plasticity. Life Sci. 60 (1997) 245-251
115. 1 receptor activation. Neuroreport 6 (1995) 1097-1100
116. de Mendonça A., Sebastião A.M., and Ribeiro J.A. Adenosine: Does it have a neuroprotective role after all?. Brain Res. Rev. 33 (2000) 258-274
117. Deckert J., Abel F., Künig G., Hartmann J., Senitz D., Maier H., Ransmayr G., and Riederer P. Loss of human hippocampal adenosine A1 receptors in dementia: Evidence for lack of specificity. Neurosci. Lett. 244 (1998) 1-4
118. Deckert J., Nothen M.M., Bryant S.P., Schuffenhauer S., Schofield P.R., Spurr N.K., and Propping P. Mapping of the human adenosine A2a receptor gene: Relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum. Genet. 99 (1997) 326-328
119. Deckert J., Nothen M.M., Franke P., Delmo C., Fritze J., Knapp M., Maier W., Beckmann H., and Propping P. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol. Psychiatry 3 (1998) 81-85
120. Deckert J., Nothen M.M., Rietschel M., Wildenauer D., Bondy B., Ertl M.A., Knapp M., Schofield P.R., Albus M., Maier W., and Propping P. Human adenosine A2a receptor (A2aAR) gene: Systematic mutation screening in patients with schizophrenia. J. Neural Transm. 103 (1996) 1447-1455
121. Delicado E.G., Sen R.P., and Miras-Portugal M.T. Effects of phorbol esters and secretagogues on nitrobenzylthioinosine binding to nucleoside transporters and nucleoside uptake in cultured chromaffin cells. Biochem. J. 279 (1991) 651-655
122. Delle Donne K.T., and Sonsalla P.K. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther. 271 (1994) 1320-1326
123. Devi L.A., and Brady L.S. Dimerization of G-protein coupled receptors. Neuropsychopharmacology 23 (2000) S3-S4
124. Díaz-Hernández M., Pereira M.F., Pintor J., Cunha R.A., Ribeiro J.A., and Miras-Portugal M.T. Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation. J. Pharmacol. Exp. Ther. 301 (2002) 441-450
125. Dickenson J.M., Blank J.L., and Hill S.J. Human adenosine A1 receptor and P2Y2-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells. Br. J. Pharmacol. 124 (1998) 1491-1499
126. DiFiglia M. Excitotoxic injury of the neostriatum: A model for Huntington's disease. Trends Neurosci. 13 (1990) 286-289
127. Diógenes M.J., Fernandes C.C., Sebastião A.M., and Ribeiro J.A. Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci. 24 (2004) 2905-2913
128. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., and Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 118 (1996) 1461-1468
129. Dixon A.K., Widdowson L., and Richardson P.J. Desensitization of the adenosine A1 receptor by the A2A receptor in the rat striatum. J. Neurochem. 69 (1997) 315-321
130. Doolette D.J. Mechanism of adenosine accumulation in the hippocampal slice during energy deprivation. Neurochem. Int. 30 (1997) 211-223
131. Doriat J.F., Humbert A.C., and Daval J.L. Brain maturation of high-affinity adenosine A2 receptors and their coupling to G-proteins. Brain Res. Dev. 93 (1996) 1-9
132. Dragunow M. Purinergic mechanisms in epilepsy. Prog. Neurobiol. 31 (1988) 85-108
133. Dragunow M., and Robertson H.A. 8-Cyclopentyl 1,3-dimethylxanthine prolongs epileptic seizures in rats. Brain Res. 417 (1987) 377-379
134. Dumas T.C., and Foster T.C. Late developmental changes in the ability of adenosine A1 receptors to regulate synaptic transmission in the hippocampus. Brain Res. Dev. 105 (1998) 137-139
135. Dunwiddie T.V. Endogenously released adenosine regulates excitability in the in vitro hippocampus. Epilepsia 21 (1980) 541-548
136. Dunwiddie T.V. The physiological role of adenosine in the central nervous system. Int. Rev. Neurobiol. 27 (1985) 63-139
137. Dunwiddie T.V. Adenosine and suppression of seizures. In: Delgado-Escuta A.V., Wilson W.A., Olsen R.W., and Porter R.J. (Eds). "Jasper's Basic Mechanisms of the Epilepsies". 3rd ed. Advances in Neurology Vol. 79 (1999), Lippincott Williams & Wilkins, Philadelphia
138. Dunwiddie T.V., and Diao L. Extracellular adenosine concentrations in hippocampal brain slices and the tonic inhibitory modulation of evoked excitatory responses. J. Pharmacol. Exp. Ther. 268 (1994) 537-545
139. Dunwiddie T.V., Diao L., and Proctor W.R. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J. Neurosci. 17 (1997) 7673-7682
140. Dunwiddie T.V., Diao L.H., Kim H.O., Jiang J.L., and Jacobson K.A. Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. J. Neurosci. 17 (1997) 607-614
141. Dunwiddie T.V., and Fredholm B.B. Adenosine neuromodulation. In: Jacobson K.A., and Jarvis M.F. (Eds). "Purinergic Approaches in Experimental Therapeutics" (1997), Wiley-Liss, New York
142. Dunwiddie T.V., and Masino S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24 (2001) 31-55
143. During M.J., and Spencer D.D. Adenosine: A potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32 (1992) 618-624
144. Eisenach J.C., Curry R., and Hood D.D. Dose response of intrathecal adenosine in experimental pain and allodynia. Anesthesiology 97 (2002) 938-942
145. Eisenach J.C., Hood D.D., and Curry R. Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 96 (2002) 29-34
146. Ekonomou A., Sperk G., Kostopoulos G., and Angelatou F. Reduction of A1 adenosine receptors in rat hippocampus after kainic acid-induced limbic seizures. Neurosci. Lett. 284 (2000) 49-52
147. El Yacoubi M., Ledent C., Menard J.F., Parmentier M., Costentin J., and Vaugeois J.M. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br. J. Pharmacol. 129 (2000) 1465-1473
148. El Yacoubi M., Ledent C., Parmentier M., Bertorelli R., Ongini E., Costentin J., and Vaugeois J.M. Adenosine A2A receptor antagonists are potential antidepressants: Evidence based on pharmacology and A2A receptor knockout mice. Br. J. Pharmacol. 134 (2001) 68-77
149. El Yacoubi M., Ledent C., Parmentier M., Costentin J., and Vaugeois J. SCH 58261 and ZM 241385 differentially prevent the motor effects of CGS 21680 in mice: Evidence for a functional 'atypical' adenosine A(2A) receptor. Eur. J. Pharmacol. 401 (2000) 63-77
150. El Yacoubi M., Ledent C., Parmentier M., Costentin J., and Vaugeois J.M. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A)
151. El Yacoubi M., Ledent C., Parmentier M., Costentin J., and Vaugeois J.M. Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy. Neuroreport 12 (2001) 983-986
152. El Yacoubi M., Ledent C., Parmentier M., Costentin J., and Vaugeois J.M. Caffeine reduces hypnotic effects of alcohol through adenosine A2A receptor blockade. Neuropharmacology 45 (2003) 977-985
153. El Yacoubi M., Ledent C., Parmentier M., Daoust M., Costentin J., and Vaugeois J.-M. Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. Neuropharmacology 40 (2001) 424-432
154. 3H]SCH 58261. Eur. J. Neurosci. 14 (2001) 1567-1570
155. Eldridge F.L., Paydarfar D., Scott S.C., and Dowell R.T. Role of endogenous adenosine in recurrent generalized seizures. Exp. Neurol. 103 (1989) 179-185
156. 3H] glutamate release from rat hippocampal slices by l-phenylisopropyladenosine. Acta Physiol. Scand. 125 (1985) 121-123
157. Fastbom J., Pazos A., and Palacios J.M. The distribution of adenosine A1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience 22 (1987) 813-826
158. Faure M., Voyno-Yasenetskaya T.A., and Bourne H.R. cAMP and beta gamma subunits of heterotrimeric G proteins stimulate the mitogen-activated protein kinase pathway in COS-7 cells. J. Biol. Chem. 269 (1994) 7851-7854
159. Fedorova I.M., Jacobson M.A., Basile A., and Jacobson K.A. Behavioral characterization of mice lacking the A3 adenosine receptor: Sensitivity to hypoxic neurodegeneration. Cell Mol. Neurobiol. 23 (2003) 431-447
160. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berlin) 133 (1997) 107-120
161. Ferré S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 (1997) 482-487
162. Ferré S., Fuxe K., von Euler G., Johansson B., and Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience 51 (1992) 501-512
163. Ferré S., Karcz-Kubicha M., Hope B.T., Popoli P., Burgueño J., Gutiérrez M.A., Casadó V., Fuxe K., Goldberg S.R., Lluis C., Franco R., and Ciruela F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA 99 (2002) 11940-11945
164. 1 receptor-mediated mechanisms. Eur. J. Neurosci. 8 (1996) 1545-1553
165. Ferré S., Popoli P., Giménez-Llort L., Rimondini R., Müller C.E., Strömberg I., Ögren S.O., and Fuxe K. Adenosine/dopamine interaction: Implications for the treatment of Parkinson's disease. Parkinsonism Relat. Disord. 7 (2001) 235-241
166. 1 receptors in stably cotransfected fibroblast cells. J. Biol. Chem. 273 (1998) 4718-4724
167. 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA 88 (1991) 7238-7241
168. 1 receptors in rat brain. Am. J. Physiol. 267 (1994) C1651-C1656
169. Fiebich B.L., Biber K., Gyufko K., Berger M., Bauer J., and van Calker D. Adenosine A2b receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglioma cells. J. Neurochem. 66 (1996) 1426-1431
170. Fiebich B.L., Biber K., Lieb K., van Calker D., Berger M., Bauer J., and Gebicke-Haerter P.J. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18 (1996) 152-160
171. Figler H., Olsson R.A., and Linden J. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract guanine nucleotide effects on agonist binding. Mol. Pharmacol. 64 (2003) 1557-1564
172. Fink J.S., Kalda A., Ryu H., Stack E.C., Schwarzschild M.A., Chen J.F., and Ferrante R.J. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88 (2004) 538-544
173. 2 dopamine receptors in rat striatum. Brain Res. Mol. 14 (1992) 186-195
174. Fiorillo C.D., and Williams J.T. Selective inhibition by adenosine of mGluR IPSPs in dopamine neurons after cocaine treatment. J. Neurophysiol. 83 (2000) 1307-1314
175. Fiser S.M., Tribble C.G., Kaza A.K., Long S.M., Kern J.A., Cassada D.C., Linden J., Rieger J., Laubach V.E., Matisoff A., and Kron I.L. Adenosine A2A receptor activation decreases reperfusion injury associated with high-flow reperfusion. J. Thorac. Cardiovasc. Surg. 124 (2002) 973-978
176. Florio C., Prezioso A., Papaioannou A., and Vertua R. Adenosine A1 receptors modulate anxiety in CD1 mice. Psychopharmacology (Berlin) 136 (1998) 311-319
177. Franco R., Casadó V., Ciruela F., Saura C., Mallol J., Canela E.I., and Lluis C. Cell surface adenosine deaminase: Much more than an ectoenzyme. Prog. Neurobiol. 52 (1997) 283-294
178. Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., Impagnatiello F., Schwarzschild M.A., and Chen J.F. Persistent behavioral sensitization to chronic l-DOPA requires A2A adenosine receptors. J. Neurosci. 22 (2002) 1054-1062
179. Fredholm B.B. Are methylxanthine effects due to antagonism of endogenous adenosine?. Trends Pharmacol. Sci. 1 (1980) 129-132
180. Fredholm B.B. Adenosine and neuroprotection. In: Green A.R., and Cross A.J. (Eds). "Neuroprotective Agents and Cerebral Ischemia" (1996), Academic Press, London
181. Fredholm B.B. Purines and neutrophil leukocytes. Gen. Pharmacol. 28 (1997) 345-350
182. Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., and Williams M. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46 (1994) 143-156
183. Fredholm B.B., Arslan G., Halldner L., Kull B., Schulte G., and Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch. Pharmacol. 362 (2000) 364-374
184. Fredholm B.B., Bättig K., Holmén J., Nehlig A., and Zvartau E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-153
185. 2A receptors and therapeutic applications. Current Topics Med. Chem. 3 (2003) 413-426
186. Fredholm B.B., and Dunwiddie T.V. How does adenosine inhibit transmitter release?. Trends Pharmacol. Sci. 9 (1988) 130-134
187. Fredholm B.B., Fuxe K., and Agnati L. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur. J. Pharmacol. 38 (1976) 31-38
188. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K.-N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
189. Fredholm B.B., Irenius E., Kull B., and Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 61 (2001) 443-448
190. Fredholm B.B., Lindström K., and Wallman-Johansson A. Propentofylline and other adenosine transport inhibitors increase the efflux of adenosine following electrical or metabolic stimulation of rat hippocampal slices. J. Neurochem. 62 (1994) 563-573
191. Frenguelli B.G., Llaudet E., and Dale N. High-resolution real-time recording with microelectrode biosensors reveals novel aspects of adenosine release during hypoxia in rat hippocampal slices. J. Neurochem. 86 (2003) 1506-1515
192. 2 receptor. Brain Res. Mol. 15 (1992) 62-66
193. Fuxe K., Ferré S., Zoli M., and Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev. 26 (1998) 258-273
194. Fuxe K., Strömberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S.O., Franco R., Agnati L.F., and Ferré S. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv. Neurol. 86 (2001) 345-353
195. Gao Y., and Phillis J.W. CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 55 (1994) 61-65
196. Gao Z.G., Kim S.G., Soltysiak K.A., Melman N., IJzerman A.P., and Jacobson K.A. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Mol. Pharmacol. 62 (2002) 81-89
197. Gebicke-Haerter P.J., Christoffel F., Timmer J., Northoff H., Berger M., and Van Calker D. Both adenosine A1- and A2-receptors are required to stimulate microglial proliferation. Neurochem. Int. 29 (1996) 37-42
198. Geiger J.D., and Fyda D.M. Adenosine transport in nervous system tissues. In: Stone T.W. (Ed). "Adenosine in the Nervous System" (1991), Academic Press, London
199. Geiger J.D., Labella F.S., and Nagy J.I. Characterization and localization of adenosine receptors in rat spinal cord. J. Neurosci. 4 (1984) 2303-2310
200. Gemba T., Oshima T., and Ninomiya M. Glutamate efflux via the reversal of the sodium-dependent glutamate transporter caused by glycolytic inhibition in rat cultured astrocytes. Neuroscience 63 (1994) 789-795
201. 1 receptor number. Brain Res. 612 (1993) 271-277
202. Gerashchenko D., Okano Y., Urade Y., Inoué S., and Hayaishi O. Strong rebound of wakefulness follows prostaglandin D2- or adenosine A2a receptor agonist-induced sleep. J. Sleep Res. 9 (2000) 81-87
203. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
204. 1 MF-2 smooth muscle cells. Mol. Pharmacol. 40 (1991) 149-155
205. Gevaerd M.S., Takahashi R.N., Silveira R., and Da Cunha C. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res. Bull. 55 (2001) 101-106
206. Ghelardini C., Galeotti N., and Bartolini A. Caffeine induces central cholinergic analgesia. Naunyn Schmiedebergs Arch. Pharmacol. 356 (1997) 590-595
207. Ghisolfi E.S., Prokopiuk A.S., Becker J., Ehlers J.A., Belmonte-de-Abreu P., Souza D.O., and Lara D.R. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects. Neuropsychopharmacology 27 (2002) 629-637
208. 1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci. 16 (2002) 547-550
209. Ginés S., Hillion J., Torvinen M., Le Crom S., Casadó V., Canela E.I., Rondin S., Lew J.Y., Watson S., Zoli M., Agnati L.F., Verniera P., Lluis C., Ferré S., Fuxe K., and Franco R. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. USA 97 (2000) 8606-8611
210. Glass M., Dragunow M., and Faull R.L. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519
211. Glass M., Faull R.L., Bullock J.Y., Jansen K., Mee E.W., Walker E.B., Synek B.J., and Dragunow M. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res. 710 (1996) 56-68
212. Greene R.W., and Haas H.L. The electrophysiology of adenosine in the mammalian central nervous system. Prog. Neurobiol. 36 (1991) 329-341
213. Grondin R., Bédard P.J., Hadj Tahar A., Grégoire L., Mori A., and Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
214. Gu J.G., Nath A., and Geiger J.D. Characterization of inhibitor-sensitive and -resistant adenosine transporters in cultured human fetal astrocytes. J. Neurochem. 67 (1996) 972-977
215. Gubitz A.K., Widdowson L., Kurokawa M., Kirkpatrick K.A., and Richardson P.J. Dual signalling by the adenosine A2a receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J. Neurochem. 67 (1996) 374-381
216. Håberg A., Qu H., Haraldseth O., Unsgård G., and Sonnewald U. In vivo effects of adenosine A1 receptor agonist and antagonist on neuronal and astrocytic intermediary metabolism studied with ex vivo 13C NMR spectroscopy. J. Neurochem. 74 (2000) 327-333
217. Hagberg H., Andersson P., Lacarewicz J., Jacobson I., Butcher S., and Sandberg M. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J. Neurochem. 49 (1987) 227-231
218. 2A receptors. Neuropharmacology 46 (2004) 1008-1017
219. 1 receptors in hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 370 (2004) 270-278
220. 2A receptor antagonist. Eur. J. Pharmacol. 406 (2000) 345-354
221. Hameleers P.A., Van Boxtel M.P., Hogervorst E., Riedel W.J., Houx P.J., Buntinx F., and Jolles J. Habitual caffeine consumption and its relation to memory, attention, planning capacity and psychomotor performance across multiple age groups. Human Psychopharm. 15 (2000) 573-581
222. 3 receptors in microglia cells. J. Neurochem. 86 (2003) 1051-1054
223. Hammer J., Qu H., Håberg A., and Sonnewald U. In vivo effects of adenosine A(2) receptor agonist and antagonist on neuronal and astrocytic intermediary metabolism studied with ex vivo (13)C MR spectroscopy. J. Neurochem. 79 (2001) 885-892
224. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297 (2002) 353-356
225. Hasko G., Kuhel D.G., Chen J.F., Schwarzschild M.A., Deitch E.A., Mabley J.G., Marton A., and Szabo C. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14 (2000) 2065-2074
226. Hauber W., and Bareiss A. Facilitative effects of an adenosine A1/A2 receptor blockade on spatial memory performance of rats: Selective enhancement of reference memory retention during the light period. Behav. Brain Res. 118 (2001) 43-52
227. Hauber W., and Koch M. Adenosine A2a receptors in the nucleus accumbens modulate prepulse inhibition of the startle response. Neuroreport 8 (1997) 1515-1518
228. Hauser R.A., Hubble J.P., and Truong D.D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
229. Hayallah A.M., Sandoval-Ramírez J., Reith U., Schobert U., Preiss B., Schumacher B., Daly J.W., and Müller C.E. 1,8-Disubstituted xanthine derivatives: Synthesis of potent A2B-selective adenosine receptor antagonists. J. Med. Chem. 45 (2002) 1500-1510
230. Heese K., Fiebich B.L., Bauer J., and Otten U. Nerve growth factor (NGF) expression in rat microglia is induced by adenosine A2a-receptors. Neurosci. Lett. 231 (1997) 83-86
231. Hersch S.M., Ciliax B.J., Gutekunst C.-A., Rees H.D., Heilman C.J., Yung K.L., Bolam J.P., Ince E., Yi H., and Levey A.I. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15 (1995) 5222-5237
232. Hettinger B.D., Lee A., Linden J., and Rosin D.L. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431 (2001) 331-346
233. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., Hansson A., Watson S., Olah M.E., Mallol J., Canela E.I., Zoli M., Agnati L.F., Ibanez C.F., Lluis C., Franco R., Ferre S., and Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 277 (2002) 18091-18097
234. Hindley S., Herman M.A., and Rathbone M.P. Stimulation of reactive astrogliosis in vivo by extracellular adenosine diphosphate or an adenosine A2 receptor agonist. J. Neurosci. Res. 38 (1994) 399-406
235. Hirani E., Gillies J., Karasawa A., Shimada J., Kase H., Opacka-Juffry J., Osman S., Luthra S.K., Hume S.P., and Brooks D.J. Evaluation of [4-O-methyl-(11)C]KW-6002 as a potential PET ligand for mapping central adenosine A(2A) receptors in rats. Synapse 42 (2001) 164-176
236. Huber A., Padrun V., Déglon N., Aebischer P., Möhler H., and Boison D. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc. Natl. Acad. Sci. USA 98 (2001) 7611-7616
237. Huston J.P., Haas H.L., Boix F., Pfister M., Decking U., Schrader J., and Schwarting R.K.W. Extracellular adenosine levels in neostriatum and hippocampus during rest and activity periods of rats. Neuroscience 73 (1996) 99-107
238. Hutchison A.J., Webb R.L., Oei H.H., Ghai G.R., Zimmerman M.B., and Williams M. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 251 (1989) 47-55
239. Ikeda K., Kurokawa M., Aoyama S., and Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80 (2002) 262-270
240. Imaizumi M., Miyazaki S., and Onodera K. Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors. Meth. Find. Exp. Clin. Pharmacol. 16 (1994) 639-644
241. 11C-labeled KF18446: A potential central nervous system adenosine A2a receptor ligand. J. Nuclear Med. 41 (2000) 345-354
242. Jacobson K.A., Nikodijevi‡ O., Shi D., Gallo-Rodriguez C., Olah M.E., Stiles G.L., and Daly J.W. A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 336 (1993) 57-60
243. Jacobson K.A., von Lubitz D.K.J.E., Daly J.W., and Fredholm B.B. Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17 (1996) 108-113
244. Jain N., Kemp N., Adeyemo O., Buchanan P., and Stone T.W. Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol. 116 (1995) 2127-2133
245. Jarvis M.F., and Williams M. Differences in adenosine A-1 and A-2 receptor density revealed by autoradiography in methylxanthine-sensitive and insensitive mice. Pharmacol. Biochem. Behav. 30 (1988) 707-714
246. 2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedebergs Arch. Pharmacol. 355 (1997) 48-56
247. 2 adenosine receptor binding and on mRNA levels in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 347 (1993) 407-414
248. 2A receptors in rat brain: Comparison with dopamine receptors. Neuroscience 80 (1997) 1187-1207
249. 3H]CGS 21680 to rat cortex differs from its binding to rat striatum. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 247 (1993) 103-110
250. 1 receptor. Proc. Natl. Acad. Sci. USA 98 (2001) 9407-9412
251. Jones P.A., Smith R.A., and Stone T.W. Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A2A receptor antagonist. Brain Res. 800 (1998) 328-335
252. Jones P.A., Smith R.A., and Stone T.W. Protection against kainate-induced excitotoxicity by adenosine A2A receptor agonists and antagonists. Neuroscience 85 (1998) 229-237
253. Joseph S.M., Buchakjian M.R., and Dubyak G.R. Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes. J. Biol. Chem. 278 (2003) 23331-23342
254. Kalinchuk A.V., Urrila A.S., Alanko L., Heiskanen S., Wigren H.K., Suomela M., Stenberg D., and Porkka-Heiskanen T. Local energy depletion in the basal forebrain increases sleep. Eur. J. Neurosci. 17 (2003) 863-869
255. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., and Jenner P. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43 (1998) 507-513
256. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., Kuwana Y., and Jenner P. Combined use of the adenosine A(2A) antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162 (2000) 321-327
257. Keil II G.J., and DeLander G.E. Spinally-mediated antinociception is induced in mice by an adenosine kinase-, but not by an adenosine deaminase-, inhibitor. Life Sci. 51 (1992) PL171, PL176
258. Kenakin T. Pharmacologic Analysis of Drug-Receptor Interaction. 2nd ed. (1993), Raven Press, New York
259. Kenakin T. Agonist-receptor efficacy I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol. Sci. 16 (1995) 188-192
260. Khan G.M., Smolders I., Ebinger G., and Michotte Y. 2-chloro-N(6)-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats. Neuropharmacology 40 (2001) 657-667
261. Kim D.S., and Palmiter R.D. Adenosine receptor blockade reverses hypophagia and enhances locomotor activity of dopamine-deficient mice. Proc. Natl. Acad. Sci. USA 100 (2003) 1346-1351
262. Kim Y.C., Ji X., Melman N., Linden J., and Jacobson K.A. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J. Med. Chem. 43 (2000) 1165-1172
263. Kirk I.P., and Richardson P.J. Inhibition of striatal GABA release by the adenosine A2a receptor is not mediated by increases in cyclic AMP. J. Neurochem. 64 (1995) 2801-2809
264. 2+-dependent manner. Neuroscience 65 (1995) 947-953
265. Klotz K.-N., Hessling J., Hegler J., Owman C., Kull B., Fredholm B.B., and Lohse M.J. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch. Pharmacol. 357 (1998) 1-9
266. Knapp C.M., Foye M.M., Cottam N., Ciraulo D.A., and Kornetsky C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 68 (2001) 797-803
267. Kobayashi S., and Millhorn D.E. Stimulation of expression for the adenosine A2A receptor gene by hypoxia in PC12 cells. A potential role in cell protection. J. Biol. Chem. 274 (1999) 20358-20365
268. Koos B.J., Maeda T., Jan C., and Lopez G. Adenosine A(2A) receptors mediate hypoxic inhibition of fetal breathing in sheep. Am. J. Obstet. Gynecol. 186 (2002) 663-668
269. Kopf S.R., Melani A., Pedata F., and Pepeu G. Adenosine and memory storage: Effect of A(1) and A(2) receptor antagonists. Psychopharmacology 146 (1999) 214-219
270. Krupnick J.G., and Benovic J.L. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 289-319
271. Kulkarni C., Joseph T., and David J. Inhibition of anticonvulsant action of carbamazepine by aminophylline and caffeine in rats. Indian J. Exp. Biol. 27 (1989) 1048-1051
272. 2A receptors. Biochem. Pharmacol. 57 (1999) 65-75
273. olf in rat striatum. Mol. Pharmacol. 58 (2000) 771-777
274. Kust B.M., Biber K., van Calker D., and Gebicke-Haerter P.J. Regulation of K+ channel mRNA expression by stimulation of adenosine A2a-receptors in cultured rat microglia. Glia 25 (1999) 120-130
275. 1 receptors, prevents the extinction of cocaine-seeking behavior in mice. J. Pharmacol. Exp. Ther. 290 (1999) 535-542
276. Lai K.M., and Wong P.C. Metabolism of extracellular adenine nucleotides by cultured rat brain astrocytes. J. Neurochem. 57 (1991) 1510-1515
277. Lang U.E., Lang F., Richter K., Vallon V., Lipp H.P., Schnermann J., and Wolfer D.P. Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice. Behav. Brain Res. 145 (2003) 179-188
278. Lara D.R., and Souza D.O. Schizophrenia: A purinergic hypothesis. Med. Hypotheses 54 (2000) 157-166
279. Latini S., and Pedata F. Adenosine in the central nervous system: Release mechanisms and extracellular concentrations. J. Neurochem. 79 (2001) 463-484
280. Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J., Costentin J., Heath J.K., Vassart G., and Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 388 (1997) 674-678
281. Lee F.S., and Chao M.V. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA 98 (2001) 3555-3560
282. Lee K.S., Schubert P., and Heinemann U. The anticonvulsive action of adenosine: A postsynaptic, dendritic action by a possible endogenous anticonvulsant. Brain Res. 321 (1984) 160-164
283. Lee Y.C., Chang C.W., Su C.W., Lin T.N., Sun S.H., Lai H.L., and Chern Y. The 5′ untranslated regions of the rat A2A adenosine receptor gene function as negative translational regulators. J. Neurochem. 73 (1999) 1790-1798
284. Lee Y.C., Chien C.L., Sun C.N., Huang C.L., Huang N.K., Chiang M.C., Lai H.L., Lin Y.S., Chou S.Y., Wang C.K., Tai M.H., Liao W.L., Lin T.N., Liu F.C., and Chern Y. Characterization of the rat A2A adenosine receptor gene: A 4.8-kb promoter-proximal DNA fragment confers selective expression in the central nervous system. Eur. J. Neurosci. 18 (2003) 1786-1796
285. Lewin E., and Bleck V. Electroshock seizures in mice: Effect on brain adenosine and its metabolites. Epilepsia 22 (1981) 577-581
286. Li X.X., Nomura T., Aihara H., and Nishizaki T. Adenosine enhances glial glutamate efflux via A2a adenosine receptors. Life Sci. 68 (2001) 1343-1350
287. Libert F., Schiffmann S.N., Lefort A., Parmentier M., Gerard C., Dumont J.E., Vanderhaeghen J.J., and Vassart G. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. EMBO J. 10 (1991) 1677-1682
288. Lin A.S., Uhde T.W., Slate S.O., and McCann U.D. Effects of intravenous caffeine administered to healthy males during sleep. Depress. Anxiety 5 (1997) 21-28
289. Linden J. Allosteric enhancement of adenosine receptors. In: Jacobson K.A., and Jarvis M.F. (Eds). "Purinergic Approaches in Experimental Therapeutics" (1997), Wiley-Liss, New York
290. Linden J., Taylor H.E., Robeva A.S., Tucker A.L., Stehle J.H., Rivkees S.A., Fink J.S., and Reppert S.M. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol. Pharmacol. 44 (1993) 524-532
291. Linden J., Thai T., Figler H., Jin X., and Robeva A.S. Characterization of human A(2B) adenosine receptors: Radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol. 56 (1999) 705-713
292. 2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience 88 (1999) 1005-1008
293. Lindskog M., Svenningsson P., Pozzi L., Kim Y., Fienberg A.A., Bibb J.A., Fredholm B.B., Nairn A.C., Greengard P., and Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418 (2002) 774-778
294. 3H]-CGS 21680 in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 354 (1996) 539-541
295. Liu F., Wan Q., Pristupa Z.B., Yu X.M., Wang Y.T., and Niznik H.B. Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature 403 (2000) 274-280
296. Lloyd H.G.E., and Fredholm B.B. Involvement of adenosine deaminase and adenosine kinase in regulating extracellular adenosine concentration in rat hippocampal slices. Neurochem. Int. 26 (1995) 387-395
297. Lobo M.G., and Ribeiro J.A. Effects of forskolin, dibutyryl cyclic AMP, and 5′-N-ethylcarboxamide adenosine on 22Na uptake by rat brain synaptosomes stimulated by veratridine. J. Neurochem. 58 (1992) 1033-1037
298. Londos C., Cooper D.M., and Wolff J. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA 77 (1980) 2551-2554
299. 1 receptor inhibition. Neuroscience 112 (2002) 319-329
300. Lopes L.V., Cunha R.A., and Ribeiro J.A. Increase in the number, G protein coupling, and efficiency of facilitatory adenosine A2A receptors in the limbic cortex, but not striatum, of aged rats. J. Neurochem. 73 (1999) 1733-1738
301. Lopes L.V., Cunha R.A., and Ribeiro J.A. Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. J. Neurophysiol. 82 (1999) 3196-3203
302. 2A receptor knockout mice. Br. J. Pharmacol. 141 (2004) 1006-1014
303. 1 receptors. Drug Dev. Res. 58 (2003) 428-438
304. Lopes L.V., Rebola N., Pinheiro P.C., Richardson P.J., Oliveira C.R., and Cunha R.A. Adenosine A3 receptors are located in neurons of the rat hippocampus. Neuroreport 14 (2003) 1645-1648
305. Lundblad M., Vaudano E., and Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. 84 (2003) 1398-1410
306. Lüscher C., Jan L.Y., Stoffel M., Malenka R.C., and Nicoll R.A. G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19 (1997) 687-695
307. Lynch M.A. Long-term potentiation and memory. Physiol. Rev. 84 (2004) 87-136
308. MacGregor D.G., Graham D.I., and Stone T.W. The attenuation of kainate-induced neurotoxicity by chlormethiazole and its enhancement by dizocilpine, muscimol, and adenosine receptor agonists. Exp. Neurol. 148 (1997) 110-123
309. MacGregor D.G., Miller W.J., and Stone T.W. Mediation of the neuroprotective action of R-phenylisopropyl-adenosine through a centrally located adenosine A1 receptor. Br. J. Pharmacol. 110 (1993) 470-476
310. Mackiewicz M., Nikonova E.V., Zimmerman J.E., Galante R.J., Zhang L., Cater J.R., Geiger J.D., and Pack A.I. Enzymes of adenosine metabolism in the brain: Diurnal rhythm and the effect of sleep deprivation. J. Neurochem. 85 (2003) 348-357
311. Madl J.E., and Burgesser K. Adenosine triphosphate depletion reverses sodium-dependent, neuronal uptake of glutamate in rat hippocampal slices. J. Neurosci. 13 (1993) 4429-4444
312. Maenhaut C., Van Sande J., Libert F., Abramowicz M., Parmentier M., Vanderhaegen J.J., Dumont J.E., Vassart G., and Schiffmann S. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Commun. 173 (1990) 1169-1178
313. Mahan L.C., McVittie L.D., Smyk-Randall E.M., Nakata H., Monsma Jr. F.J., Gerfen C.R., and Sibley D.R. Cloning and expression of an A1 adenosine receptor from rat brain. Mol. Pharmacol. 40 (1991) 1-7
314. Maia L., and de Mendonça A. Does caffeine intake protect from Alzheimer's disease?. Eur. J. Neurol. 9 (2002) 377-382
315. Manzoni O., Pujalte D., Williams J., and Bockaert J. Decreased presynaptic sensitivity to adenosine after cocaine withdrawal. J. Neurosci. 18 (1998) 7996-8002
316. Marangos P.J. Potential therapeutic roles for adenosine in neurologic disease. In: Stone T.W. (Ed). "Adenosine in the Nervous System" (1991), Academic Press, London
317. Marangos P.J., von Lubitz D., Daval J.L., and Deckert J. Adenosine: Its relevance to the treatment of brain ischemia and trauma. Prog. Clin. Biol. Res. 361 (1990) 331-349
318. Marchi M., Raiteri L., Risso F., Vallarino A., Bonfanti A., Monopoli A., Ongini E., and Raiteri M. Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br. J. Pharmacol. 136 (2002) 434-440
319. Marcoli M., Raiteri L., Bonfanti A., Monopoli A., Ongini E., Raiteri M., and Maura G. Sensitivity to selective adenosine A1 and A2A receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. Neuropharmacology 45 (2003) 201-210
320. Marks G.A., Shaffery J.P., Speciale S.G., and Birabil C.G. Enhancement of rapid eye movement sleep in the rat by actions at A1 and A2a adenosine receptor subtypes with a differential sensitivity to atropine. Neuroscience 116 (2003) 913-920
321. Martinez-Mir M.I., Probst A., and Palacios J.M. Adenosine A2 receptors: Selective localization in the human basal ganglia and alterations with disease. Neuroscience 42 (1991) 697-706
322. 1 receptors. J. Pharmacol. Exp. Ther. 303 (2002) 356-363
323. Mauborgne A., Poliénor H., Hamon M., Cesselin F., and Bourgoin S. Adenosine receptor-mediated control of in vitro release of pain-related neuropeptides from the rat spinal cord. Eur. J. Pharmacol. 441 (2002) 47-55
324. Mayne M., Fotheringham J., Yan H.J., Power C., Del Bigio M.R., Peeling J., and Geiger J.D. Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann. Neurol. 49 (2001) 727-735
325. Mendelson W.B. Sleep-inducing effects of adenosine microinjections into the medial preoptic area are blocked by flumazenil. Brain Res. 852 (2000) 479-481
326. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: From structure to function. Physiol. Rev. 78 (1998) 189-225
327. Mitchell I.J., Cooper A.J., and Griffiths M.R. The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59 (1999) 691-719
328. Mitchell J.B., Lupica C.R., and Dunwiddie T.V. Activity-dependent release of endogenous adenosine modulates synaptic responses in the rat hippocampus. J. Neurosci. 13 (1993) 3439-3447
329. Mody I., and MacDonald J.F. NMDA receptor-dependent excitotoxicity: The role of intracellular Ca2+ release. Trends Pharmacol. Sci. 16 (1995) 356-359
330. Mogul D.J., Adams M.E., and Fox A.P. Differential activation of adenosine receptors decreases N-type but potentiates P-type Ca2+ current in hippocampal CA3 neurons. Neuron 10 (1993) 327-334
331. Monopoli A., Lozza G., Forlani A., Mattavelli A., and Ongini E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9 (1998) 3955-3959
332. Moo-Puc R.E., Góngora-Alfaro J.L., Alvarez-Cervera F.J., Pineda J.C., Arankowsky-Sandoval G., and Heredia-López F. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology 45 (2003) 493-503
333. 2A receptors: An overview. Brain Res. Brain Res. Rev. 31 (1999) 65-82
334. Morelli M., Fenu S., Pinna A., and Di Chiara G. Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 251 (1994) 21-25
335. Morelli M., and Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol. Sci. 22 (2001) 71-72
336. Mori A., Shindou T., Ichimura M., Nonaka H., and Kase H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16 (1996) 605-611
337. Murillo-Rodriguez E., Blanco-Centurion C., Gerashchenko D., Salin-Pascual R.J., and Shiromani P.J. The diurnal rhythm of adenosine levels in the basal forebrain of young and old rats. Neuroscience 123 (2004) 361-370
338. Myers D.E., Shaikh Z., and Zullo T.G. Hypoalgesic effect of caffeine in experimental ischemic muscle contraction pain. Headache 37 (1997) 654-658
339. Naassila M., Ledent C., and Daoust M. Low ethanol sensitivity and increased ethanol consumption in mice lacking adenosine A2A receptors. J. Neurosci. 22 (2002) 10487-10493
340. Nagy A.K., Houser C.R., and Delgado-Escueta A.V. Synaptosomal ATPase activities in temporal cortex and hippocampal formation of humans with focal epilepsy. Brain Res. 529 (1990) 192-201
341. Nash J.E., and Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors: Implications for the treatment of Parkinson's disease. J. Neurosci. 20 (2000) 7782-7789
342. 6-cyclohexyl adenosine (CHA) on isolation-induced aggression in male mice. Meth. Find. Exp. Clin. Pharmacol. 22 (2000) 43-46
343. Neary J.T., McCarthy M., Kang Y., and Zuniga S. Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. Neurosci. Lett. 242 (1998) 159-162
344. Newby A.C. Adenosine and the concept of "retaliatory metabolites.". Trends Biochem. 9 (1984) 42-44
345. Newby A.C. Adenosine: Origin and clinical roles. Adv. Exp. Med. Biol. 309A (1991) 265-270
346. Newman E.A. Glial cell inhibition of neurons by release of ATP. J. Neurosci. 23 (2003) 1659-1666
347. Ngai A.C., Coyne E.F., Meno J.R., West G.A., and Winn H.R. Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles. Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H2329-H2335
348. Nicolas F., Oillet J., Koziel V., and Daval J.L. Characterization of adenosine receptors in a model of cultured neurons from rat forebrain. Neurochem. Res. 19 (1994) 507-515
349. Nikbakht M.R., and Stone T.W. Suppression of presynaptic responses to adenosine by activation of NMDA receptors. Eur. J. Pharmacol. 427 (2001) 13-25
350. Nishi A., Bibb J.A., Snyder G.L., Higashi H., Nairn A.C., and Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA 97 (2000) 12840-12845
351. Nishizaki T., Nagai K., Nomura T., Tada H., Kanno T., Tozaki H., Li X.X., Kondoh T., Kodama N., Takahashi E., Sakai N., Tanaka K., and Saito N. A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors. Glia 39 (2002) 133-147
352. Noguchi J., Ishiwata K., Furuta R., Simada J., Kiyosawa M., Ishii S., Endo K., Suzuki F., and Senda M. Evaluation of carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligand. Nucl. Med. Biol. 24 (1997) 53-59
353. Norenberg W., Wirkner K., Assmann H., Richter M., and Illes P. Adenosine A2A receptors inhibit the conductance of NMDA receptor channels in rat neostriatal neurons. Amino Acids 14 (1998) 33-39
354. O'Regan M.H., Simpson R.E., Perkins L.M., and Phillis J.W. The selective A2 adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci. Lett. 138 (1992) 169-172
355. Ochiishi T., Takita M., Ikemoto M., Nakata H., and Suzuki S.S. Immunohistochemical analysis on the role of adenosine A1 receptors in epilepsy. Neuroreport 10 (1999) 3535-3541
356. Ogata T., Nakamura Y., and Schubert P. Potentiated cAMP rise in metabotropically stimulated rat cultured astrocytes by a Ca2+-related A1/A2 adenosine receptor cooperation. Eur. J. Neurosci. 8 (1996) 1124-1131
357. Ohta A., and Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414 (2001) 916-920
358. Okusa M.D., Linden J., Huang L., Rieger J.M., Macdonald T.L., and Huynh L.P. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am. J. Physiol. Renal Physiol. 279 (2000) F809-F818
359. Olah M.E., and Stiles G.L. The role of receptor structure in determining adenosine receptor activity. Pharmacol. Ther. 85 (2000) 55-75
360. Olsson R.A., and Pearson J.D. Cardiovascular purinoceptors. Physiol. Rev. 70 (1990) 761-845
361. 1 receptor gene does not alter neuronal damage following ischemia in mouse in vivo and in vitro. Eur. J. Neurol 20 (2004) 1197-1204
362. Ongini E., Adami M., Ferri C., and Bertorelli R. Adenosine A2A receptors and neuroprotection. Ann. N. Y. Acad. Sci. 825 (1997) 30-48
363. Ongini E., Dionisotti S., Gessi S., Irenius E., and Fredholm B.B. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 359 (1999) 7-10
364. Ongini E., and Fredholm B.B. Pharmacology of adenosine A2A receptors. Trends Pharmacol. Sci. 17 (1996) 364-372
365. Othman T., Yan H., and Rivkees S.A. Oligodendrocytes express functional A1 adenosine receptors that stimulate cellular migration. Glia 44 (2003) 166-172
366. Oztas E., Xu K., Kalda A., Irrizary M., Schwarzschild M.A., and Chen J.-F. Caffeine attenuates MPTP-induced loss of dopaminergic neurons in substantia nigra in mice. Paper presented at the Society for Neuroscience Annual Meeting, Orlando, Florida (2002)
367. Pagonopoulou O., and Angelatou F. Reduction of A1 adenosine receptors in cortex, hippocampus and cerebellum in ageing mouse brain. Neuroreport 3 (1992) 735-737
368. Pagonopoulou O., and Angelatou F. Time development and regional distribution of [3H]nitrobenzylthioinosine adenosine uptake site binding in the mouse brain after acute pentylenetetrazol-induced seizures. J. Neurosci. Res. 53 (1998) 433-442
369. Pappagallo M., Gaspardone A., Tomai F., Iamele M., Crea F., and Gioffré P.A. Analgesic effect of bamiphylline on pain induced by intradermal injection of adenosine. Pain 53 (1993) 199-204
370. 3H]-CGS 21680 as a ligand. Naunyn Schmiedebergs Arch. Pharmacol. 342 (1990) 85-89
371. Pereira G.S., Mello e Souza T., Vinadé E.R., Choi H., Rodrigues C., Battastini A.M., Izquierdo I., Sarkis J.J., and Bonan C.D. Blockade of adenosine A1 receptors in the posterior cingulate cortex facilitates memory in rats. Eur. J. Pharmacol. 437 (2002) 151-154
372. Phillis J.W. The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705 (1995) 79-84
373. Phillis J.W., and Goshgarian H.G. Adenosine and neurotrauma: Therapeutic perspectives. Neurol. Res. 23 (2001) 183-189
374. Phillis J.W., Walter G.A., O'Regan M.H., and Stair R.E. Increases in cerebral cortical perfusate adenosine and inosine concentrations during hypoxia and ischemia. J. Cereb. Blood Flow Metab. 7 (1987) 679-686
375. Phillis J.W., and Wu P.H. The role of adenosine and its nucleotides in central synaptic transmission. Prog. Neurobiol. 16 (1981) 187-239
376. Picano E., and Abbracchio M.P. Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res. Bull. 52 (2000) 75-82
377. Pierce R.C., and Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res. Rev. 25 (1997) 192-216
378. 2A adenosine receptors positively modulates turning behaviour and c-fos expression induced by D-1 agonists in dopamine-denervated rats. Eur. J. Neurosci. 8 (1996) 1176-1181
379. Pinna A., Fenu S., and Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39 (2001) 233-238
380. Pitsikas N., and Borsini F. The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat. Eur. J. Pharmacol. 328 (1997) 19-22
381. Pollack A.E., and Fink J.S. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68 (1995) 721-728
382. Pollack A.E., and Fink J.S. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res. 743 (1996) 124-130
383. Popoli P., Betto P., Rimondini R., Reggio R., Pezzola A., Ricciarello G., Fuxe K., and Ferre S. Age-related alteration of the adenosine/dopamine balance in the rat striatum. Brain Res. 795 (1998) 297-300
384. Popoli P., Pézzola A., Reggio R., Caporali M.G., and Scotti de Carolis A. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease. Eur. J. Pharmacol. 257 (1994) R5-R6
385. Popoli P., Pintor A., Domenici M.R., Frank C., Tebano M.T., Pèzzola A., Scarchilli L., Quarta D., Reggio R., Malchiodi-Albedi F., Falchi M., and Massotti M. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22 (2002) 1967-1975
386. Popoli P., Reggio R., Pezzola A., Fuxe K., and Ferré S. Adenosine A1 and A2A receptor antagonists stimulate motor activity: Evidence for an increased effectiveness in aged rats. Neurosci. Lett. 251 (1998) 201-204
387. Porkka-Heiskanen T., Alanko L., Kalinchuk A., and Stenberg D. Adenosine and sleep. Sleep Med. Rev. 6 (2002) 321-332
388. Porkka-Heiskanen T., Strecker R.E., Thakkar M., Bjorkum A.A., Greene R.W., and McCarley R.W. Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness. Science 276 (1997) 1265-1268
389. Portas C.M., Thakkar M., Rainnie D.G., Greene R.W., and McCarley R.W. Role of adenosine in behavioral state modulation: A microdialysis study in the freely moving cat. Neuroscience 79 (1997) 225-235
390. 2a selective adenosine receptor antagonist. Br. J. Pharmacol. 115 (1995) 1096-1102
391. Proctor W.R., and Dunwiddie T.V. Pre- and postsynaptic actions of adenosine in the in vitro rat hippocampus. Brain Res. 426 (1987) 187-190
392. Qu W.M., Huang Z.L., Mochizuki T., Taniike M.T., Eguchi N., Chen J.-F., Urade Y., and Hayashi O. Adenosine A2A receptor deficiency attenuates somnogenic effect of prostaglandin D2. Paper presented at the Society for Neuroscience Annual Meeting, Orlando, Florida (2002)
393. Queiroz G., Gebicke-Haerter P.J., Schobert A., Starke K., and von Kügelgen I. Release of ATP from cultured rat astrocytes elicited by glutamate receptor activation. Neuroscience 78 (1997) 1203-1208
394. Queiroz G., Talaia C., and Gonçalves J. Adenosine A2A receptor-mediated facilitation of noradrenaline release involves protein kinase C activation and attenuation of presynaptic inhibitory receptor-mediated effects in the rat vas deferens. J. Neurochem. 85 (2003) 740-748
395. Radulovacki M. Role of adenosine in sleep in rats. Rev. Clin. Basic Pharm. 5 (1985) 327-339
396. Radulovacki M., Virus R.M., Djuricic-Nedelson M., and Green R.D. Adenosine analogs and sleep in rats. J. Pharmacol. Exp. Ther. 228 (1984) 268-274
397. Rainnie D.G., Grunze H.C., McCarley R.W., and Greene R.W. Adenosine inhibition of mesopontine cholinergic neurons: Implications for EEG arousal. Science 263 (1994) 689-692 [published erratum in Science 1994 Jul 1, 265, 16]
398. Rajagopal R., Chen Z.Y., Lee F.S., and Chao M.V. Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J. Neurosci. 24 (2004) 6650-6658
399. Rathbone M.P., Middlemiss P.J., Gysbers J.W., Andrew C., Herman M.A., Reed J.K., Ciccarelli R., Di Iorio P., and Caciagli F. Trophic effects of purines in neurons and glial cells. Prog. Neurobiol. 59 (1999) 663-690
400. Rebola N., Coelho J.E., Costenla A.R., Lopes L.V., Parada A., Oliveira C.R., Soares-da-Silva P., de Mendonça A., and Cunha R.A. Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur. J. Neurosci. 18 (2003) 820-828
401. Rebola N., Oliveira C.R., and Cunha R.A. Transducing system operated by adenosine A(2A) receptors to facilitate acetylcholine release in the rat hippocampus. Eur. J. Pharmacol. 454 (2002) 31-38
402. Rebola N., Pinheiro P.C., Oliveira C.R., Malva J.O., and Cunha R.A. Subcellular localization of adenosine A(1) receptors in nerve terminals and synapses of the rat hippocampus. Brain Res. 987 (2003) 49-58
403. Rebola N., Porciúncula L.O., Oliveira C.R., Soares-da-Silva P., and Cunha R.A. Long-term effect of convulsive behaviour on the density of adenosine A1 and A2A receptors in the rat cerebral cortex. Epilepsia (2004)
404. Rebola N., Sebastião A.M., de Mendonca A., Oliveira C.R., Ribeiro J.A., and Cunha R.A. Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J. Neurophysiol. 90 (2003) 1295-1303
405. Reddington M., and Pusch R. Adenosine metabolism in a rat hippocampal slice preparation: Incorporation into S-adenosylhomocysteine. J. Neurochem. 40 (1983) 285-290
406. Reggio R., Pèzzola A., and Popoli P. The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res. 831 (1999) 315-318
407. Ren H., and Stiles G.L. Separate promoters in the human A1 adenosine receptor gene direct the synthesis of distinct messenger RNAs that regulate receptor abundance. Mol. Pharmacol. 48 (1995) 975-980
408. Ren H., and Stiles G.L. A single-stranded DNA binding site in the human A1 adenosine receptor gene promoter. Mol. Pharmacol. 53 (1998) 43-51
409. Ren H., and Stiles G.L. Dexamethasone stimulates human A1 adenosine receptor (A1AR) gene expression through multiple regulatory sites in promoter B. Mol. Pharmacol. 55 (1999) 309-316
410. 1 adenosine receptor gene. J. Biol. Chem. 269 (1994) 3104-3110
411. Reppert S.M., Weaver D.R., Stehle J.H., and Rivkees S.A. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol. Endocrinol. 5 (1991) 1037-1048
412. Ribeiro J.A. Purinergic inhibition of neurotransmitter release in the central nervous system. Pharmacol. Toxicol. 77 (1995) 299-305
413. Ribeiro J.A., Sebastião A.M., and de Mendonça A. Adenosine receptors in the nervous system: Pathophysiological implications. Prog. Neurobiol. 68 (2002) 377-392
414. Ribeiro J.A., Sebastiao A.M., and de Mendonca A. Participation of adenosine receptors in neuroprotection. Drug News Perspect. 16 (2003) 80-86
415. Richardson P.J., Dixon A.K., Lee K., Bell M.I., Cox P.J., Williams R., Pinnock R.D., and Freeman T.C. Correlating physiology with gene expression in striatal cholinergic neurones. J. Neurochem. 74 (2000) 839-846
416. Richardson P.J., Gubitz A.K., Freeman T.C., and Dixon A.K. Adenosine receptor antagonists and Parkinson's disease: Actions of the A2A receptor in the striatum. Adv. Neurol. 80 (1999) 111-119
417. Rimondini R., Ferré S., Gimenez-Llort L., Ögren S.O., and Fuxe K. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats. Eur. J. Pharmacol. 347 (1998) 153-158
418. Rimondini R., Ferré S., Ögren S.O., and Fuxe K. Adenosine A2A agonists: A potential new type of atypical antipsychotic. Neuropsychopharmacology 17 (1997) 82-91
419. Rivkees S.A. The ontogeny of cardiac and neural A1 adenosine receptor expression in rats. Brain Res. Dev. Brain Res. 89 (1995) 202-213
420. Rivkees S.A., Chen M., Kulkarni J., Browne J., and Zhao Z. Characterization of the murine A1 adenosine receptor promoter, potent regulation by GATA-4 and Nkx2.5. J. Biol. Chem. 274 (1999) 14204-14209
421. Rivkees S.A., Price S.L., and Zhou F.C. Immunohistochemical detection of A1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res. 677 (1995) 193-203
422. Rivkees S.A., Thevananther S., and Hao H. Are A3 adenosine receptors expressed in the brain?. Neuroreport 11 (2000) 1025-1030
423. Rivkees S.A., Zhao Z., Porter G., and Turner C. Influences of adenosine on the fetus and newborn. Mol. Genet. Metab. 74 (2001) 160-171
424. Robinson T.E., and Berridge K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction [Review]. Brain Res. Brain Res. Rev. 18 (1993) 247-291
425. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., and Patel Y.C. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science 288 (2000) 154-157
426. Rochon D., Rousse I., and Robitaille R. Synapse-glia interactions at the mammalian neuromuscular junction. J. Neurosci. 21 (2001) 3819-3829
427. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem (2004)
428. Roelen H., Veldman N., Spek A.L., von Frijtag Drabbe Kunzel J., Mathot R.A., and IJzerman A.P. N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors. J. Med. Chem. 39 (1996) 1463-1471
429. Rogers P.J., and Dernoncourt C. Regular caffeine consumption: A balance of adverse and beneficial effects for mood and psychomotor performance. Pharmacol. Biochem. Behav. 59 (1998) 1039-1045
430. Ronan P.J., Wang C.D., Brambilla D., Thompson M., and Greene R.W. The role of adenosine A1 receptors in sleep and behavioral arousal; focal gene deletion using the CRE-LOXP system. Paper presented at the Society for Neuroscience Annual Meeting, Orlando, Florida (2002)
431. Rosenberg P.A., and Li Y. Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by beta-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. Brain Res. 692 (1995) 227-232
432. Rosin D.L., Robeva A., Woodard R.L., Guyenet P.G., and Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol. 401 (1998) 163-186
433. Ross G.W., Abbott R.D., Petrovitch H., Morens D.M., Grandinetti A., Tung K.H., Tanner C.M., Masaki K.H., Blanchette P.L., Curb J.D., Popper J.S., and White L.R. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
434. Rudolphi K.A., Schubert P., Parkinson F.E., and Fredholm B.B. Adenosine and brain ischemia. Cerebrovasc. Brain Metab. Rev. 4 (1992) 346-369
435. Rudolphi K.A., Schubert P., Parkinson F.E., and Fredholm B.B. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol. Sci. 13 (1992) 439-445
436. Salvatore C.A., Jacobson M.A., Taylor H.E., Linden J., and Johnson R.G. Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA 90 (1993) 10365-10369
437. Salvatore C.A., Tilley S.L., Latour A.M., Fletcher D.S., Koller B.H., and Jacobson M.A. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275 (2000) 4429-4434
438. Sandoli D., Chiu P.J., Chintala M., Dionisotti S., and Ongini E. In vivo and ex vivo effects of adenosine A1 and A2 receptor agonists on platelet aggregation in the rabbit. Eur. J. Pharmacol. 259 (1994) 43-49
439. Satoh S., Matsumura H., and Hayaishi O. Involvement of adenosine A2A receptor in sleep promotion. Eur. J. Pharmacol. 351 (1998) 155-162
440. Satoh S., Matsumura H., Koike N., Tokunaga Y., Maeda T., and Hayaishi O. Region-dependent difference in the sleep-promoting potency of an adenosine A2A receptor agonist. Eur. J. Neurosci. 11 (1999) 1587-1597
441. 2 in rats. Proc. Natl. Acad. Sci. USA 93 (1996) 5980-5984
442. Sattin A., and Rall T.W. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′, 5′ phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. 6 (1970) 13-23
443. Sawynok J., and Liu X.J. Adenosine in the spinal cord and periphery: Release and regulation of pain. Prog. Neurobiol. 69 (2003) 313-340
444. Scammell T.E., Gerashchenko D.Y., Mochizuki T., McCarthy M.T., Estabrooke I.V., Sears C.A., Saper C.B., Urade Y., and Hayaishi O. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 107 (2001) 653-663
445. Scanziani M., Capogna M., Gähwiler B.H., and Thompson S.M. Presynaptic inhibition of miniature excitatory synaptic currents by baclofen and adenosine in the hippocampus. Neuron 9 (1992) 919-927
446. Schenk S., Worley C.M., McNamara C., and Valadez A. Acute and repeated exposure to caffeine: Effects on reinstatement of extinguished cocaine-taking behavior in rats. Psychopharmacology 126 (1996) 17-23
447. Schiffmann S.N., Jacobs O., and Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: An in situ hybridization histochemistry study. J. Neurochem. 57 (1991) 1062-1067
448. Schiffmann S.N., Libert F., Vassart G., and Vanderhaeghen J.J. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci. Lett. 130 (1991) 177-181
449. Schiffmann S.N., and Vanderhaeghen J.J. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13 (1993) 1080-1087
450. Schiffmann S.N., and Vanderhaeghen J.J. Age-related loss of mRNA encoding adenosine A2 receptor in the rat striatum. Neurosci. Lett. 158 (1993) 121-124
451. Schindler M., Harris C.A., Hayes B., Papotti M., and Humphrey P.P. Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci. Lett. 297 (2001) 211-215
452. Schoen S.W., Ebert U., and Löscher W. 5′-Nucleotidase activity of mossy fibers in the dentate gyrus of normal and epileptic rats. Neuroscience 93 (1999) 519-526
453. Schrader J., Schütz W., and Bardenheuer H. Role of S-adenosylhomocysteine hydrolase in adenosine metabolism in mammalian heart. Biochem. J. 196 (1981) 65-70
454. 3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol. Pharmacol. 58 (2000) 477-482
455. 1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations. Neuroscience 121 (2003) 907-916
456. Schwarzschild M.A., Chen J.F., and Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 58 (2002) 1154-1160
457. Schwierin B., Borbely A.A., and Tobler I. Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur. J. Pharmacol. 300 (1996) 163-171
458. Sciotti V.M., and Van Wylen D.G. Attenuation of ischemia-induced extracellular adenosine accumulation by homocysteine. J. Cereb. Blood Flow Metab. 13 (1993) 208-213
459. Sebastião A.M., Cunha R.A., de Mendonça A., and Ribeiro J.A. Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. Br. J. Pharmacol. 131 (2000) 1629-1634
460. Sebastião A.M., Macedo M.P., and Ribeiro J.A. Tonic activation of A(2A) adenosine receptors unmasks, and of A(1) receptors prevents, a facilitatory action of calcitonin gene-related peptide in the rat hippocampus. Br. J. Pharmacol. 129 (2000) 374-380
461. Sebastiao A.M., and Ribeiro J.A. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 48 (1996) 167-189
462. Sebastião A.M., and Ribeiro J.A. Fine-tuning neuromodulation by adenosine. Trends Pharmacol. Sci. 21 (2000) 341-346
463. Shimada Y., Ishiwata K., Kiyosawa M., Nariai T., Oda K., Toyama H., Suzuki F., Ono K., and Senda M. Mapping adenosine A(1) receptors in the cat brain by positron emission tomography with [(11)C]MPDX. Nucl. Med. Biol. 29 (2002) 29-37
464. Shimazoe T., Yoshimatsu A., Kawashimo A., and Watanabe S. Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization. Eur. J. Pharmacol. 388 (2000) 249-254
465. Shin H.K., Shin Y.W., and Hong K.W. Role of adenosine A(2B) receptors in vasodilation of rat pial artery and cerebral blood flow autoregulation. Am. J. Physiol. Heart Circ. Physiol. 278 (2000) H339-H344
466. Shindou T., Mori A., Kase H., and Ichimura M. Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus. J. Physiol. (Lond.) 532 (2001) 423-434
467. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., and Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berlin) 147 (1999) 90-95
468. Sigworth L.A., and Rea M.A. Adenosine A1 receptors regulate the response of the mouse circadian clock to light. Brain Res. 960 (2003) 246-251
469. Silinsky E.M., Hirsh J.K., Searl T.J., Redman R.S., and Watanabe M. Quantal ATP release from motor nerve endings and its role in neurally mediated depression. Prog. Brain Res. 120 (1999) 145-158
470. Solinas M., Ferré S., You Z.B., Karcz-Kubicha M., Popoli P., and Goldberg S.R. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J. Neurosci. 22 (2002) 6321-6324
471. Sollevi A., Belfrage M., Lundeberg T., Segerdahl M., and Hansson P. Systemic adenosine infusion: A new treatment modality to alleviate neuropathic pain. Pain 61 (1995) 155-158
472. Soudijn W., van Wijngaarden I., and IJzerman A.P. Allosteric modulation of G protein-coupled receptors. Curr. Opin. Drug Discov. Dev. 5 (2002) 749-755
473. Sperlágh B., Zsilla G., Baranyi M., Kékes-Szabó A., and Vizi E.S. Age-dependent changes of presynaptic neuromodulation via A1-adenosine receptors in rat hippocampal slices. Int. J. Dev. Neurosci. 15 (1997) 739-747
474. Stehle J.H., Rivkees S.A., Lee J.J., Weaver D.R., Deeds J.D., and Reppert S.M. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol. Endocrinol. 6 (1992) 384-393
475. Stein E., Zou Y., Poo M., and Tessier-Lavigne M. Binding of DCC by netrin-1 to mediate axon guidance independent of adenosine A2B receptor activation. Science 291 (2001) 1976-1982
476. 1-receptor knockout mice. Paper presented at the Society for Neuroscience 32nd Annual Meeting, Orlando, Florida (2002)
477. 2A receptors. Nucl. Med. Biol. 24 (1997) 187-191
478. Strecker R.E., Morairty S., Thakkar M.M., Porkka-Heiskanen T., Basheer R., Dauphin L.J., Rainnie D.G., Portas C.M., Greene R.W., and McCarley R.W. Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav. Brain Res. 115 (2000) 183-204
479. Strecker R.E., Porkka-Heiskanen T., Thakkar M.M., Dauphin L.J., Stenberg D., and McCarley R.W. Recent evidence that the sleep-promoting effects of adenosine are site specific. Sleep 22 (1999) S32
480. 1 receptor-induced gene transcription is modulated by DARPP-32. J. Neurochem. 75 (2000) 248-257
481. Svenningsson P., Fourreau L., Bloch B., Fredholm B.B., Gonon F., and Le Moine C. Opposite tonic modulation of dopamine and adenosine on c-fos mRNA expression in striatopallidal neurons. Neuroscience 89 (1999) 827-837
482. 2A receptors in rat brain. J. Pharmacol. Exp. Ther. 280 (1997) 1094-1101
483. Svenningsson P., Hall H., Sedvall G., and Fredholm B.B. Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. Synapse 27 (1997) 322-335
484. Svenningsson P., Le Moine C., Fisone G., and Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59 (1999) 355-396
485. 2A receptors. Proc. Natl. Acad. Sci. USA 97 (2000) 1856-1860
486. 1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84 (1998) 223-228
487. Svenningsson P., Nomikos G.G., and Fredholm B.B. The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J. Neurosci. 19 (1999) 4011-4022
488. Swanson T.H., Drazba J.A., and Rivkees S.A. Adenosine A1 receptors are located predominantly on axons in the rat hippocampal formation. J. Comp. Neurol. 363 (1995) 517-531
489. Sylvén C., Jonzon B., Brandt R., and Beermann B. Adenosine-provoked angina pectoris-like pain-time characteristics, influence of autonomic blockade and naloxone. Eur. Heart J. 8 (1987) 738-743
490. Tabrizchi R., and Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol. Ther. 91 (2001) 133-147
491. Tasch E., Cendes F., Li L.M., Dubeau F., Andermann F., and Arnold D.L. Neuroimaging evidence of progressive neuronal loss and dysfunction in temporal lobe epilepsy. Ann. Neurol. 45 (1999) 568-576
492. Tetzlaff W., Schubert P., and Kreutzberg G.W. Synaptic and extrasynaptic localization of adenosine binding sites in the rat hippocampus. Neuroscience 21 (1987) 869-875
493. Thakkar M.M., Winston S., and McCarley R.W. A1 receptor and adenosinergic homeostatic regulation of sleep-wakefulness: Effects of antisense to the A1 receptor in the cholinergic basal forebrain. J. Neurosci. 23 (2003) 4278-4287
494. Thompson S.M., Haas H.L., and Gähwiler B.H. Comparison of the actions of adenosine at pre- and postsynaptic receptors in the rat hippocampus in vitro. J. Physiol. (Lond.) 451 (1992) 347-363
495. Trincavelli M.L., Costa B., Tuscano D., Lucacchini A., and Martini C. Up-regulation of A(2A) adenosine receptors by proinflammatory cytokines in rat PC12 cells. Biochem. Pharmacol. 64 (2002) 625-631
496. Turner C.P., Blackburn M.R., and Rivkees S.A. A1 adenosine receptors mediate hypoglycemia-induced neuronal injury. J. Mol. Endocrinol. 32 (2004) 129-144
497. Turner C.P., Seli M., Ment L., Stewart W., Yan H., Johansson B., Fredholm B.B., Blackburn M., and Rivkees S.A. A1 adenosine receptors mediate hypoxia-induced ventriculomegaly. Proc. Natl. Acad. Sci. USA 100 (2003) 11718-11722
498. Turner C.P., Yan H., Schwartz M., Othman T., and Rivkees S.A. A1 adenosine receptor activation induces ventriculomegaly and white matter loss. Neuroreport 13 (2002) 1199-1204
499. van Calker D., Muller M., and Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33 (1979) 999-1005
500. van der Wenden E.M., Carnielli M., Roelen H.C., Lorenzen A., von Frijtag Drabbe Kunzel J.K., and IJzerman A.P. 5′-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor. J. Med. Chem. 41 (1998) 102-108
501. Varani K., Merighi S., Gessi S., Klotz K.N., Leung E., Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., and Borea P.A. [(3)H]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol. Pharmacol. 57 (2000) 968-975
502. 2A receptor deficient mice are more resistant to seizures. Eur. J. Neurosci (2003)
503. Vizi E.S., and Sperlágh B. Receptor- and carrier-mediated release of ATP of postsynaptic origin: Cascade transmission. Prog. Brain Res. 120 (1999) 159-169
504. Von Lubitz D.K. Adenosine in the treatment of stroke: Yes, maybe, or absolutely not?. Expert Opin. Invest. Drugs 10 (2001) 619-632
505. Von Lubitz D.K., Carter M.F., Beenhakker M., Lin R.C., and Jacobson K.A. Adenosine: A prototherapeutic concept in neurodegeneration. Ann. N. Y. Acad. Sci. 765 (1995) 163-178
506. 3 receptor stimulation on seizures in mice. Eur. J. Pharmacol. 275 (1995) 23-29
507. Von Lubitz D.K., Lin R.C., and Jacobson K.A. Cerebral ischemia in gerbils: Effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Eur. J. Pharmacol. 287 (1995) 295-302
508. Von Lubitz D.K., Lin R.C., Melman N., Ji X.D., Carter M.F., and Jacobson K.A. Chronic administration of selective adenosine A1 receptor agonist or antagonist in cerebral ischemia. Eur. J. Pharmacol. 256 (1994) 161-167
509. Von Lubitz D.K., Paul I.A., Ji X.D., Carter M., and Jacobson K.A. Chronic adenosine A1 receptor agonist and antagonist: Effect on receptor density and N-methyl-d-aspartate induced seizures in mice. Eur. J. Pharmacol. 253 (1994) 95-99
510. Wang J.H., Short J., Ledent C., Lawrence A.J., and Buuse M. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav. Brain Res. 143 (2003) 201-207
511. Ward N., Whitney C., Avery D., and Dunner D. The analgesic effects of caffeine in headache. Pain 44 (1991) 151-155
512. Weber J.G., Ereth M.H., and Danielson D.R. Perioperative ingestion of caffeine and postoperative headache. Mayo Clin. Proc. 68 (1993) 842-845
513. Weisberg S.P., and Kaplan G.B. Adenosine receptor antagonists inhibit the development of morphine sensitization in the C57BL/6 mouse. Neurosci. Lett. 264 (1999) 89-92
514. Wetherington J.P., and Lambert N.A. Differential desensitization of responses mediated by presynaptic and postsynaptic A1 adenosine receptors. J. Neurosci. 22 (2002) 1248-1255
515. Whitcomb K., Lupica C.R., Rosen J.B., and Berman R.F. Adenosine involvement in postictal events in amygdala-kindled rats. Epilepsy Res. 6 (1990) 171-179
516. Wieraszko A., and Seyfried T.N. Increased amount of extracellular ATP in stimulated hippocampal slices of seizure prone mice. Neurosci. Lett. 106 (1989) 287-293
517. Winn H.R., Morii S., and Berne R.M. The role of adenosine in autoregulation of cerebral blood flow. Ann. Biomed. Eng. 13 (1985) 321-328
518. Winn H.R., Welsh J.E., Rubio R., and Berne R.M. Changes in brain adenosine during bicuculline-induced seizures in rats. Effects of hypoxia and altered systemic blood pressure. Circ. Res. 47 (1980) 568-577
519. Wittendorp M.C., Boddeke H.W., and Biber K. Adenosine A3 receptor-induced CCL2 synthesis in cultured mouse astrocytes. Glia 46 (2004) 410-418
520. Worley C.M., Valadez A., and Schenk S. Reinstatement of extinguished cocaine-taking behavior by cocaine and caffeine. Pharmacol. Biochem. Behav. 48 (1994) 217-221
521. 3 receptors. Neuroscience 114 (2002) 523-527
522. Xu K., Xu Y.H., Chen J.F., and Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322 (2002) 13-16
523. Yamamoto S., Nakanishi O., Matsui T., Shinohara N., Kinoshita H., Lambert C., and Ishikawa T. Intrathecal adenosine A1 receptor agonist attenuates hyperalgesia without inhibiting spinal glutamate release in the rat. Cell. Mol. Neurobiol. 23 (2003) 175-185
524. Yoshioka K., Hosoda R., Kuroda Y., and Nakata H. Hetero-oligomerization of adenosine A1 receptors with P2Y1 receptors in rat brains. FEBS Lett. 531 (2002) 299-303
525. Yoshioka K., Saitoh O., and Nakata H. Heteromeric association creates a P2Y-like adenosine receptor. Proc. Natl. Acad. Sci. USA 98 (2001) 7617-7622
526. Young D., and Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience 58 (1994) 245-261
527. Yu L., Frith M.C., Suzuki Y., Peterfreund R.A., Gearan T., Sugano S., Schwarzschild M.A., Weng Z., Fink J.S., and Chen J.F. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Res. 1000 (2004) 156-173
528. Yung K.K.L., Bolam J.P., Smith A.D., Hersch S.M., Ciliax B.J., and Levey A.I. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy. Neuroscience 65 (1995) 709-730
529. 2 receptors. J. Neurosci. 20 (2000) 5949-5957
530. Zhang G., Franklin P.H., and Murray T.F. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther. 264 (1993) 1415-1424
531. Zhou Q.Y., Li C., Olah M.E., Johnson R.A., Stiles G.L., and Civelli O. Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor. Proc. Natl. Acad. Sci. USA 89 (1992) 7432-7436
532. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch. Pharmacol. 362 (2000) 299-309